News - Amgen, Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 28 results

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Amgen and UCB’s romosozumab shows significant increase in BMD

Amgen and UCB’s romosozumab shows significant increase in BMD

02-01-2014

US biotech firm Amgen and partner UCB of Belgium have announced positive results from a Phase II trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyForteoFosamaxResearchromosozumabUCB

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA

19-09-2013

The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

SOBI restructures Kineret and Kepivance deals

09-09-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

Generics triple-therapy just as effective as brand-name Enbrel, new study shows

13-06-2013

Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in…

AmgenAnti-Arthritics/RheumaticsEnbrelGenericsmethotrexatePharmaceuticalResearch

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Unigene and Nordic Bioscience amend JDV accord; Amgen Vectibix China deal

10-05-2013

USA-based Unigene Laboratories (PINK: UGNE) has entered into an equity transfer and exclusive license…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDiabetesLicensingMergers & AcquisitionsNordic BioscienceOncologyPharmaceuticalUGP302Unigene LabsVectibixZhejiang Beta Pharma

Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar

17-04-2013

USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

Thought leader views on new osteoporosis and osteopenia treatments

05-04-2013

US and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is…

AMG-785AmgenAnti-Arthritics/RheumaticsBiotechnologyCDP-7851Eli LillyEuropeHealthcareMarkets & MarketingMerck & CoNorth AmericaodanacatibPharmaceuticalteriparatideUCB

Switch to anabolics driving osteoporosis market growth

11-03-2013

A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

UCB and Amgen not to progress development of romosozumab for fracture healing

13-02-2013

Belgium's leading drugmaker UCB (Euronext Brussels: UCB) and its partner, US biotech giant Amgen (Nasdaq:…

AmgenAnti-Arthritics/RheumaticsBiotechnologyPharmaceuticalResearchromosozumabUCB

Global rheumatology market controlled by Enbrel, Humira and Remicade

24-12-2012

The global rheumatology therapeutics market has been forecast to increase at a compound annual growth…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyCelebrexEnbrelGlaxoSmithKlineGlobalHumiraMarkets & MarketingPfizerPharmaceuticalRemicadeTakeda PharmaceuticalsUloric

ASBMR 2012: Anabolics and post-marketing studies

25-10-2012

This year's American Society for Bone and Mineral Research (ASBMR) conference, held in Minneapolis, Minnesota,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEli LillyMerck & CoodanacatibPharmaceuticalProliaResearchteriparatideUnigene Labs

New data on Amgen's Prolia and Merck & Co's odanacatib presented at ASBMR meeting

15-10-2012

Amgen (Nasdaq: AMGN), the world's largest biotech firm, has presented data from several Prolia (denosumab)…

AmgenAnti-Arthritics/RheumaticsBiotechnologyMerck & CoodanacatibPharmaceuticalProliaResearchWomen's Health

Bristol-Myers' subcutaneous Orencia OKed in EU; Biologics for RA

07-10-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) announced on Friday that the European Commission has granted…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEnbrelEuropeHumiraMarkets & MarketingNorth AmericaOrenciaPfizerPharmaceuticalRegulation

Amgen's Prolia gets FDA nod for men with osteoporosis

24-09-2012

The US Food and Drug Administration last week approved a new indication for world biotech leader Amgen's…

AmgenAnti-Arthritics/RheumaticsBiotechnologyMen's HealthNorth AmericaProliaRegulation

Enbrel gets highest rating among RA biologicals by surveyed US patients

02-09-2012

For surveyed rheumatoid arthritis (RA) patients on biologic therapy, the benefits outweigh the risks…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEnbrelMarkets & MarketingmethotrexateNorth AmericaPfizerPharmaceutical

Abbott/Eisai's Humira has emerged as leading psoriasis agent

07-08-2012

For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

AstraZeneca collaborates with Amgen on five MAbs

03-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

Daiichi Sankyo files denosumab in Japan for osteoporosis

26-03-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) revealed on Friday that it has filed for approval in Japan…

AmgenAnti-Arthritics/RheumaticsAsia-PacificDaiichi SankyodenosumabPharmaceuticalRegulation

Global osteoporosis market report sees strong showing in China

01-02-2012

The global market for drugs to treat osteoporosis was estimated to be worth $7.3 billion in 2010 and…

AmgenAnti-Arthritics/RheumaticsAsia-PacificGlobalMarkets & MarketingPharmaceuticalXgeva

Amgen’s gets new US patent for Enbrel, giving protection until 2028

24-11-2011

Global biotech leader Amgen (Nasdaq: AMN) has announced the issuance of a new patent, US Patent No 8,063,182,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEnbrelNorth AmericaPatentsPharmaceuticalRoche

1 to 25 of 28 results

Back to top